polycystic ovarian syndrome. Sclerocystic ovary syndrome Stein-Leventhal syndrome
Conditions
Interventions
Intervention 1: Intervention group: Vitex agnus tablet, containing standardized pure extract of Vitex agnus fruits with 2.1 to 3.3 mg acubin, two pills daily for three cycles of 28 days . Interventi
Treatment - Drugs
Intervention group: Vitex agnus tablet, containing standardized pure extract of Vitex agnus fruits with 2.1 to 3.3 mg acubin, two pills daily for three cycles of 28 days .
Control group: LD tablet, containing 30 mcg ethinyl estradiol and 150 mcg levonorgestrel, one pill daily for first 21 days of each cycle through three cycles of 28 days. The last seven tablets in LD g
Sponsors
Research deputy of Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: oligomenorrhea or amenorrhea (menstrual intervals longer than 35 days or no menstruation in the last three months); polycystic ovarian confirmed by ultrasound; age 45-18 years; willingness to participate in the study; Body mass index between 18 and 35. Exclusion criteria: having other androgenic disorders such as adrenal hyperplasia or androgen-producing tumors; contraindications of oral contraceptive LD including: smokers over 35 years, active liver diseases, systolic blood pressure equal to or above 140 mm Hg and diastolic equal to or above 90 mm Hg , diabetes for more than 20 years, gallbladder diseases, history of stroke, blood clots in the legs or lungs, heart attack and other cardiovascular problems, breast cancer, migraine with aura,... ; thyroid diseases; cushing's syndrome; currently taking oral contraceptives or other hormonal treatments; pregnancy; breastfeeding; history of surgery on one or both ovaries; taking dopamine antagonist drugs such Thioridazine, Promazine, Metoclopramide, Hydroxyzine, etc
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Menstrual cycle length. Timepoint: One month, two months, three months after the intervention. Method of measurement: Calendar. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum Dehydroepiandrosterone sulfate level. Timepoint: Before the intervention and three months after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Serum free testosterone level. Timepoint: Before the intervention and three months after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Serum prolactin levels. Timepoint: Before the intervention and three months after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactParvaneh Ghahremani nasab
Tabriz University of Medical Sciences
Outcome results
None listed